Valuation: Solid Biosciences Inc.

Market Cap 849M 737M 687M 631M 1.19B 80.72B 1.21B 8.1B 3.17B 40.35B 3.19B 3.12B 134B P/E 2026 *
-4.4x
P/E 2027 * -4.43x
Enterprise Value 623M 541M 505M 464M 877M 59.29B 886M 5.95B 2.33B 29.64B 2.34B 2.29B 98.2B EV / Sales 2026 *
-
EV / Sales 2027 * 61.2x
Free-Float
87.17%
Yield 2026 *
-
Yield 2027 * -
1 day+7.48%
1 week+8.16%
Current month+6.95%
1 month-20.48%
3 months+19.23%
6 months+32.21%
Current year+52.84%
1 week 7.75
Extreme 7.75
8.71
1 month 7.65
Extreme 7.65
11.45
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 1.81
Extreme 1.81
15.05
5 years 1.81
Extreme 1.81
51.3
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Chief Executive Officer 55 2022-12-01
Corporate Officer/Principal - 2014-08-31
Director of Finance/CFO 48 2023-01-08
Director TitleAgeSince
Director/Board Member 52 2013-02-28
Director/Board Member 60 2015-10-31
Director/Board Member 46 2015-10-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Fiscal year

Chairman

6,880 0.0070%
6/10/26 Free

Founder

77,500 0.0787%
2/13/26 Fiscal year

Chief Operating Officer

36,843 0.0473%
Change 5-day change 1-year change 3-year change Capi.($)
+7.48%+8.16%+26.39%+129.87% 849M
+10.00%+14.90%+53.89%+87.07% 62.53B
+1.62%-4.56%+23.57%+67.43% 52.43B
-0.98%-1.19%-16.98%-14.21% 23.1B
+0.30%-5.17%-11.23%+349.07% 21.4B
+0.05%+0.37%+30.96%-26.25% 17.76B
+4.29%+8.97%+200.03%+341.85% 15.47B
+2.08%-1.17%+13.58%+612.75% 14.68B
+1.71%-0.90%+52.13%+176.27% 14.08B
+4.16%+4.44%+444.12%+183.06% 12.62B
Average +3.07%+1.71%+81.65%+190.69% 23.49B
Weighted average by Cap. +3.73%+1.85%+60.35%+148.31%

Financials

2026 *2027 *
Net sales - 11.08M 9.62M 8.97M 8.24M 15.59M 1.05B 15.76M 106M 41.36M 527M 41.62M 40.71M 1.75B
Net income -232M -201M -187M -172M -326M -22.03B -329M -2.21B -864M -11.01B -870M -851M -36.48B -255M -221M -206M -190M -359M -24.25B -363M -2.43B -951M -12.12B -957M -936M -40.17B
Net Debt -225M -196M -182M -168M -317M -21.44B -320M -2.15B -841M -10.72B -846M -828M -35.51B -170M -148M -138M -127M -240M -16.22B -242M -1.63B -636M -8.11B -640M -626M -26.86B
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
26-08-04 US$8.620 +7.48% 921,249
26-08-03 US$8.020 -0.50% 905,525
26-07-31 US$8.060 -5.06% 1,060,573
26-07-30 US$8.490 +5.60% 845,994
26-07-29 US$8.040 +0.88% 905,025
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
8.620USD
Average target price
17.73USD
Spread / Average Target
+105.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SLDB Stock